Brightgene Bio-medical Technology Co (SHSE:688166) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Brightgene Bio-medical Technology Co EBITDA Margin % Related Terms
Brightgene Bio-medical Technology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co EBITDA Margin % Chart
SHSE:688166 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Brightgene Bio-medical Technology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brightgene Bio-medical Technology Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brightgene Bio-medical Technology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Brightgene Bio-medical Technology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co (SHSE:688166) has a EBITDA Margin % of 4.65% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Brightgene Bio-medical Technology Co and its competitors. This is 82% below median its historical median of 25.71. Over the past decade, Brightgene Bio-medical Technology Co's EBITDA Margin % has ranged from 6.84 to 31.10. According to the industry distribution chart, Brightgene Bio-medical Technology Co ranks #265 out of 937 companies in the Biotechnology industry, placing it in the top 28.3%.
Is Brightgene Bio-medical Technology Co's EBITDA Margin % too high?
Brightgene Bio-medical Technology Co's current EBITDA Margin % of 4.65% is 82% below median its 10-year median of 25.71. Over the past 10 years, this metric has ranged from a low of 6.84 to a high of 31.10. Based on the distribution chart, Brightgene Bio-medical Technology Co ranks #265 out of 937 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brightgene Bio-medical Technology Co ranks #265 out of 937 companies for EBITDA Margin %. This puts Brightgene Bio-medical Technology Co in the upper half of its industry. Historically, Brightgene Bio-medical Technology Co's own EBITDA Margin % has ranged from 6.84 to 31.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Brightgene Bio-medical Technology Co and its competitors. Brightgene Bio-medical Technology Co's current EBITDA Margin % is 4.65%, which is 82% below median its own 10-year median of 25.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.49, compared to a current price of ¥31.19 — trading 19% below its estimated fair value. The current EBITDA Margin % is 4.65%, which is 82% below median its 10-year median of 25.71. Brightgene Bio-medical Technology Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current EBITDA Margin % is 4.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued.
The current stock price of ¥31.19 is trading 19% below its estimated GF Value™ of ¥38.49.
GuruFocus considers Brightgene Bio-medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688166:
EBITDA Margin %: 4.65% (82% below median its 10-year median of 25.71)
GF Value™: ¥38.49 vs. price of ¥31.19 (19% below fair value)
No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brightgene Bio-medical Technology Co Business Description
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
84GF Score
Get the complete analysis for SHSE:688166
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688166 has been successfully added to your 
